INTRODUCTION {#s1}
============

The RecQ like helicase 4 (*RECQL4*) gene encodes a helicase essential for repairing DNA damage and maintaining genomic stability ([@MCS004218MACC23]). Pathogenic homozygous or compound heterozygous variants affecting *RECQL4* cause three clinically overlapping autosomal recessive (AR) disorders, namely Rothmund--Thomson syndrome (RTS), Baller--Gerold syndrome (BGS), and RAPADILINO (RAdial ray defect, PAtellar aplasia/arched or cleft PAlate, DIarrhea/Disclosed joints, LIttle size/LImb malformation, NOse slender/NOrmal intelligence) syndrome ([@MCS004218MACC47]). Rothmund--Thomson syndrome is the most prevalent of these syndromes, with nononcologic features including poikiloderma; sparse hair, eyelashes, and eyebrows; short stature; dental abnormalities; dysplastic or poorly formed nails; and gastrointestinal problems in infancy ([@MCS004218MACC38]). BGS is the rarest of these disorders and is characterized by craniosynostosis, radial ray defects, short stature, and malformed or missing patellae ([@MCS004218MACC46]). Finally, RAPADILINO syndrome is characterized by short stature, radial and patellar aplasia or hypoplasia, absence of thumbs, dislocation of joints, highly arched palate, infantile diarrhea, and pigmentary changes or café au lait macules ([@MCS004218MACC37]). A predisposition to cancer has been reported in all three syndromes, with the highest cancer occurrence in RTS. Patients with RTS, and to a lesser degree RAPADILINO, are at greatest risk to develop osteosarcoma (OS) ([@MCS004218MACC37]; [@MCS004218MACC5]; [@MCS004218MACC47]), whereas patients with all three conditions are at risk for lymphoma ([@MCS004218MACC46]; [@MCS004218MACC38]).

Through a clinical research protocol (NCT02530658), we identified a child with OS for whom germline whole-exome and whole-genome sequencing (WGS) and in-depth analysis of 156 cancer predisposition genes revealed a pathogenic alteration and a variant of uncertain significance (VUS) in *RECQL4*, with the variants present *in trans*. In light of evolving evidence that heterozygous germline variants affecting other DNA repair genes such as *ATM*, *BRCA2*, and *PALB2* confer an increased cancer risk ([@MCS004218MACC44]; [@MCS004218MACC33]; [@MCS004218MACC3]; [@MCS004218MACC14]; [@MCS004218MACC31]; [@MCS004218MACC13]; [@MCS004218MACC12]), we questioned whether heterozygous germline *RECQL4* variants, such as the one observed in our patient, might be associated with development of pediatric cancer. To address this question, we analyzed 5562 children with cancer and identified a significant enrichment of heterozygous *RECQL4* loss-of-function (LOF) variants in patients with OS. Notably, most children carried the same *RECQL4* alteration: c.1573delT (p.Cys525Alafs), which is predicted to truncate the RECQL4 protein within its DNA helicase domain. *RECQL4* LOF variants were rarely observed in children with other cancer types, in which they were not significantly enriched compared to noncancer controls.

RESULTS {#s2}
=======

Characteristics of the Index Case {#s2a}
---------------------------------

A 16-yr-old girl with previously treated OS of the left tibia developed recurrent OS of the left femur and left wrist, 5 and 8 yr after the initial diagnosis, respectively. Family history revealed a maternal first cousin with an unspecified brain tumor at 3 yr of age ([Fig. 1](#MCS004218MACF1){ref-type="fig"}). The maternal grandparents developed cancer after 60 yr of age, but no other family members were reported to have cancer. Germline WGS performed as part of a clinical research protocol (NCT02530658) that comprehensively analyzed 156 cancer predisposition genes ([Supplemental Table 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004218/-/DC1)) revealed no pathogenic or likely pathogenic (P/LP) variants in known OS genes such as *TP53*, *RB1*, the mismatch repair, and Fanconi anemia genes. However, testing did reveal two rare variants in *RECQL4*, including a frameshift c.1573delT (p.Cys525Alafs) and an in-frame deletion of nine nucleotides that is predicted to remove three amino acids c.2412_2420del (p.Ala805_Arg807del) ([Table 1](#MCS004218MACTB1){ref-type="table"}). These variants were classified by a CLIA-certified laboratory as pathogenic and of uncertain significance, respectively, based on the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) guidelines for sequence variant interpretation ([@MCS004218MACC34]).

![Three-generation pedigree of a 16-yr-old female with recurrent osteosarcoma (arrowhead). Circles and squares denote female and male family members, respectively, and shaded figures denote persons with cancer. The individuals age in years (yr), age at diagnosis (dx.), and age at death (d.) are indicated on the pedigree where applicable. (NOS) Not otherwise specified.](MCS004218Mac_F1){#MCS004218MACF1}

###### 

Germline *RECQL4* variants identified in the index case

  Gene       Chr   Location      Exon   HGVS DNA           HGVS protein         Variant type        dbSNP ID      Genotype       Parent of origin   Variant allele frequency   Coverage   Clinical significance in ClinVar   Comments
  ---------- ----- ------------- ------ ------------------ -------------------- ------------------- ------------- -------------- ------------------ -------------------------- ---------- ---------------------------------- ------------------------
  *RECQL4*   8     144,514,983   9      c.1573delT         p.Cys525Alafs\*33    Frameshift          Rs386833845   Heterozygous   Mother             0.277                      90         P                                  Mother is heterozygous
  *RECQL4*   8     144,513,269   15     c.2412\_ 2420del   p.Ala805_Arg807del   In-frame deletion   Rs766312203   Heterozygous   Father             0.308                      13         VUS                                Father is homozygous

On physical examination, the patient was well-developed with no dysmorphic facial features. She had relatively thin hair and eyebrows, which by the patient\'s account predated chemotherapy. Her height was about 2nd percentile for age and in proportion to the calculated midparental height (height = 148 cm, midparental height = 153.5 cm). Although her head circumference was small, it was in proportion to her height and weight. Approximately 12 café au lait macules were observed on the patient\'s trunk and buttocks ranging in size from 4 mm to 4 cm; scattered hypopigmented areas on her left thigh and trunk were also observed. No axillary freckling was observed, and none of the skin lesions were consistent with poikiloderma. Based on the clinical phenotype, the patient did not meet the diagnostic criteria for RTS ([@MCS004218MACC47]) by the account of two clinical geneticists who examined the patient on multiple occasions and/or reviewed multiple photographs highlighting close-up views of the face, stature, and pigmented skin lesions. The patient\'s parents had no clinical features of RTS and no personal history of cancer. Based on parental testing, the two variants found in the patient were determined to be on opposite chromosomes (*in trans*). This testing revealed that the patient\'s father was homozygous for the c.2412_2420del (p.Ala805_Arg807del) VUS. The absence of RTS features in the father provided supporting evidence that this VUS was likely benign or that it is a hypomorphic allele that does not have a phenotype when found in the homozygous state but may play some role in this patient\'s unusual phenotype when opposite a loss-of-function variant. The patient\'s mother was heterozygous for the pathogenic c.1573delT (p.Cys525Alafs) variant. The patient\'s brother was not reported to have any clinical features of RTS and no personal history of cancer. He did not opt to pursue genetic testing and as a result, his *RECQL4* genetic status remains unknown.

Prevalence of Heterozygous Germline *RECQL4* LOF Variants in Pediatric Cancer {#s2b}
-----------------------------------------------------------------------------

Heterozygous pathogenic variants in DNA damage repair genes (e.g., *ATM*, *BRCA2*, *PALB2*) are associated with a moderate to high cancer risk ([@MCS004218MACC44]; [@MCS004218MACC33]; [@MCS004218MACC3]; [@MCS004218MACC14]; [@MCS004218MACC31]; [@MCS004218MACC13]; [@MCS004218MACC12]), whereas compound heterozygous or homozygous variants confer syndromic presentations such as ataxia-telangiectasia (*ATM*) ([@MCS004218MACC41]; [@MCS004218MACC1]) and Fanconi anemia (*BRCA2*, *PALB2*) ([@MCS004218MACC16]; [@MCS004218MACC32]), which confer an even greater cancer risk. Building upon this notion, we sought to determine whether heterozygous *RECQL4* LOF variants are more prevalent in pediatric oncology patients as compared to control individuals not selected for cancer. Among 4435 pediatric cancer patients at St. Jude Children\'s Research Hospital ([@MCS004218MACC50]; [@MCS004218MACC49]) and 1127 in the National Cancer Institute TARGET database (dbGaP accession phs000218.v20.p7), we identified 24 of 5562 (0.43%) who carried heterozygous *RECQL4* LOF variants ([Table 2](#MCS004218MACTB2){ref-type="table"}), including five of 249 (2.0%) with OS ([Fig. 2](#MCS004218MACF2){ref-type="fig"}).

![Frequency of heterozygous *RECQL4* LOF mutations across pediatric cancer types. (OS) osteosarcoma, (GCT) germ cell tumor, (HL) Hodgkin lymphoma, (ALL) acute lymphoblastic leukemia, (NHL) non-Hodgkin lymphoma, (AML) acute myeloid leukemia, (CNS) central nervous system, (LOF) loss-of-function.](MCS004218Mac_F2){#MCS004218MACF2}

###### 

Heterozygous germline *RECQL4* LOF variants detected in pediatric sequencing cohorts

  Subject ID      Cancer diagnosis                    Age at diagnosis   Ethnicity of subject   Gene       Chr   Location (hg38)   Exon   HGVS DNA                   HGVS protein          Variant class                Variant allele frequency   Coverage   dbSNP ID       Clinical significance in ClinVar   AF in gnomad noncancer v2.1   Ethnicity-specific AF in gnomAD noncancer v2.1   Cohort
  --------------- ----------------------------------- ------------------ ---------------------- ---------- ----- ----------------- ------ -------------------------- --------------------- --------------- ------- ---- -------------------------- ---------- -------------- ---------------------------------- ----------------------------- ------------------------------------------------ --------
  SJCNS044968     Craniopharyngioma                   5                  NFE                    *RECQL4*   8     144,516,696       5      c.423delG                  p.Lys141Asnfs\*39     Frameshift      0.294   34   NA                         NA         \-             \-                                 NA                            NA                                               SJCRH
  SJALL016422     Acute B-lymphoblastic leukemia      NA                 NFE^b^                 *RECQL4*   8     144,516,254       5      c.865delG                  p.Ala289Leufs\*4      Frameshift      NA      NA   0.687                      32         \-             \-                                 NA                            NA                                               TARGET
  SJALL019720     Acute lymphoblastic leukemia, NOS   11                 NFE                    *RECQL4*   8     144,516,248       5      c.871delG                  p.Ala291Leufs\*2      Frameshift      0.409   22   0.545                      33         rs1389647533   P                                  4.28 × 10^−06^                9.85 × 10^−06^                                   SJCRH
  SJALL015934     Acute B-lymphoblastic leukemia      NA                 SAS^b^                 *RECQL4*   8     144,515,890       7      c.1132-2A\>G               p.Ala378_E6splice     Splice          NA      NA   0.510                      249        \-             \-                                 4.29 × 10^−06^                3.28 × 10^−05^                                   TARGET
  SJALL019022     Acute B-lymphoblastic leukemia      3                  NFE                    *RECQL4*   8     144,515,243       7      c.1391-1G\>A               p.Glu464_E8splice     Splice          0.423   26   0.750                      16         rs117642173    P                                  2.89 × 10^−05^                6.59 × 10^−05^                                   SJCRH
  SJAML007029     Acute myeloid leukemia              11                 NFE                    *RECQL4*   8     144,514,983       9      c.1573delT                 p.Cys525Alafs\*33     Frameshift      0.567   30   0.550                      20         rs386833845    P                                  2.43 × 10^−04^                4.21 × 10^−04^                                   SJCRH
  SJOS019534      Osteosarcoma                        6                  NFE                    *RECQL4*   8     144,514,983       9      c.1573delT                 p.Cys525Alafs\*33     Frameshift      0.355   31   0.429                      28         rs386833845    P                                  2.43 × 10^−04^                4.21 × 10^−04^                                   SJCRH
  SJCBF029        Acute myelogeneous leukemia         11                 NFE                    *RECQL4*   8     144,514,983       9      c.1573delT                 p.Cys525Alafs\*33     Frameshift      NA      NA   0.571                      28         rs386833845    P                                  2.43 × 10^−04^                4.21 × 10^−04^                                   SJCRH
  SJBALL030048    Acute B-lymphoblastic leukemia      3                  NFE^c^                 *RECQL4*   8     144,514,983       9      c.1573delT                 p.Cys525Alafs\*33     Frameshift      0.218   64   0.315                      200        rs386833845    P                                  2.43 × 10^−04^                4.21 × 10^−04^                                   SJCRH
  SJOS030129^a^   Osteosarcoma                        8                  AMR^c^                 *RECQL4*   8     144,514,983       9      c.1573delT                 p.Cys525Alafs\*33     Frameshift      NA      NA   0.277                      90         rs386833845    P                                  2.43 × 10^−04^                1.42 × 10^−04^                                   SJCRH
  SJALL041208     Acute B-lymphoblastic leukemia      4                  NFE                    *RECQL4*   8     144,514,983       9      c.1573delT                 p.Cys525Alafs\*33     Frameshift      0.4     30   0.470                      66         rs386833845    P                                  2.43 × 10^−04^                2.43 × 10^−04^                                   SJCRH
  SJGCT041514     Germ cell tumor, testicular         0.3                NFE                    *RECQL4*   8     144,514,983       9      c.1573delT                 p.Cys525Alafs\*33     Frameshift      0.364   44   0.473                      55         rs386833845    P                                  2.43 × 10^−04^                2.43 × 10^−04^                                   SJCRH
  SJBALL002191    Acute B-lymphoblastic leukemia      NA                 NFE^b^                 *RECQL4*   8     144,514,983       9      c.1573delT                 p.Cys525Alafs\*33     Frameshift      NA      NA   0.293                      58         rs386833845    P                                  2.43 × 10^−04^                2.43 × 10^−04^                                   TARGET
  SJTALL022098    Acute T-lymphoblastic leukemia      10                 AMR^b^                 *RECQL4*   8     144,514,983       9      c.1573delT                 p.Cys525Alafs\*33     Frameshift      NA      NA   0.545                      11         rs386833845    P                                  2.43 × 10^−04^                1.44 × 10^−04^                                   TARGET
  SJHL019300      Hodgkin lymphoma                    7                  AFR                    *RECQL4*   8     144,514,363       10     c.1705-1delG               p.Ile569_E11splice    Splice          0.364   44   0.500                      10         \-             \-                                 NA                            NA                                               SJCRH
  SJST030131      Spindle cell sarcoma                16                 AFR^c^                 *RECQL4*   8     144,514,350       11     c.1717C\>T                 p.Gln573\*            Nonsense        0.275   58   0.25                       8          \-             \-                                 3.19 × 10^−05^                1.15 × 10^−04^                                   SJCRH
  SJTALL065       Acute T-lymphoblastic leukemia      8                  AFR                    *RECQL4*   8     144,513,592       13     c.2178\_ 2179insCCTGGGTC   p.Ala727Profs\*119    Frameshift      NA      NA   0.2                        73         \-             \-                                 NA                            NA                                               SJCRH
  SJOS040215      Osteosarcoma                        NA                 NFE^b^                 *RECQL4*   8     144,513,412       14     c.2269C\>T                 p.Gln757\*            Nonsense        NA      NA   0.503                      153        rs137853229    P                                  1.24 × 10^−04^                1.45 × 10^−04^                                   TARGET
  SJOS040163      Osteosarcoma                        NA                 NFE^b^                 *RECQL4*   8     144,513,383       15     c.2296+1C\>G               p.Arg766_E15splice    Splice          NA      NA   0.357                      26         rs199605511    \-                                 NA                            NA                                               TARGET
  SJNHL019456     Non-Hodgkin lymphoma                7                  NFE                    *RECQL4*   8     144,513,109       16     c.2492_2493delAT           p.His831Argfs\*52     Frameshift      0.263   19   0.064                      47         rs752729755    P                                  7.02 × 10^−05^                7.01 × 10^−05^                                   SJCRH
  SJHL042013      Hodgkin lymphoma                    18                 NFE                    *RECQL4*   8     144,513,109       16     c.2492_2493delAT           p.His831Argfs\*52     Frameshift      0.5     34   0.400                      5          rs752729755    P                                  7.02 × 10^−05^                7.01 × 10^−05^                                   SJCRH
  SJOS040168      Osteosarcoma                        NA                 NFE^b^                 *RECQL4*   8     144,512,846       16     c.2755+1G\>A               p.Ala919_E16splice    Splice          NA      NA   0.316                      19         rs373130543    \-                                 3.16 × 10^−05^                2.86 × 10^−05^                                   TARGET
  SJALL019726     Acute B-lymphoblastic leukemia      3                  NFE                    *RECQL4*   8     144,513,109       19     c.3073_3074delAG           p.Thr1024_Glu1025fs   Frameshift      0.44    25   0.385                      39         \-             \-                                 NA                            NA                                               SJCRH
  SJRB001130      Retinoblastoma                      NA                 OTH                    *RECQL4*   8     144,511,911       20     c.3393+2T\>G               p.Arg1131_E20splice   Splice          0.6     15   NA                         NA         rs557284122    \-                                 1.52 × 10^−05^                0.00 × 10^+00^                                   SJCRH

All ethnicities were computationally predicted unless otherwise noted. All predicted populations were consistent with self-reporting unless otherwise noted.

(LOF) Loss of function, (WGS) whole-genome sequencing, (WES) whole-exome sequencing.

^a^Index case.

^b^Self-reporting not available.

^c^Self-reported ethnicity only.

To determine whether these LOF variants are enriched in children with cancer, we examined their prevalence in the Genome Aggregation Database (gnomAD v2.1, noncancer; [@MCS004218MACC20]), which spans 118,479 whole-exome and 15,708 whole-genome sequences from individuals who were not ascertained for having cancer. There were a total of 385 *RECQL4* LOF alleles in the gnomAD noncancer population after removal of the founder variant, c.1390+2delT (p.Ala420_Ala463del), which is commonly encountered in the Finnish population at a minor allele frequency of 0.4% ([@MCS004218MACC20]) but was absent from our cohort. Low-confidence LOF variants and variants of dubious quality were also removed as detailed in the Methods. Compared to the noncancer cohort in gnomAD, we observed a significant association between heterozygous *RECQL4* LOF variants and OS (*P* = 0.00087; OR = 7.1; 95% CI, 2.9--17.0) but no association for other tumor types. One patient with retinoblastoma was noted to harbor an additional pathogenic variant in *RB1* and was excluded from subsequent analysis. Available tumor data from 12 germline *RECQL4* LOF variant positive cases did not show loss of heterozygosity for *RECQL4* or any pathogenic or likely pathogenic variants in the remaining *RECQL4* allele.

Evaluation of *RECQL4* Genotype and Association with Clinical Phenotype {#s2c}
-----------------------------------------------------------------------

To understand how germline *RECQL4* LOF variants impacted the encoded protein, we evaluated their location within the gene. Among the 24 variants identified, 17 (71%) resided within the helicase domain (residues 489--850; [Fig. 3](#MCS004218MACF3){ref-type="fig"}), which is critical to maintaining genome stability, specifically in the case of DNA repair ([@MCS004218MACC6]; [@MCS004218MACC8]). All variants in the helicase domain are predicted to result in NMD or a disrupted protein product. Four of 24 (17%) patients harbored germline *RECQL4* variants amino-terminal to the helicase domain, all of which are predicted to cause nonsense-mediated decay (NMD). Of these, three were located in a region having sequence similarity to yeast Sld2 (the Sld2-like domain; residues 1--388), which is essential for the initiation of DNA replication, and the fourth was located in a nuclear targeting signal (residues 363--492) ([@MCS004218MACC7]). Three of 24 patients had variants located carboxy-terminal to the helicase domain, in exons 16 and 19, which are also predicted to cause NMD.

![Distribution of the germline heterozygous *RECQL4* LOF mutations in the pediatric cancer cohort examined in this study and in gnomAD noncancer v2.1. Known domains of the RECQL4 protein are as shown.](MCS004218Mac_F3){#MCS004218MACF3}

Notably, nine (38%) of the *RECQL4* LOF variant--positive individuals were noted to carry the same alteration, c.1573delT (p.Cys525Alafs), which was also present in our index case ([Fig. 3](#MCS004218MACF3){ref-type="fig"}). Patients with this variant carried diagnoses of acute lymphoblastic leukemia (ALL; *n* = 4), OS (*n* = 2), acute myeloid leukemia (AML; *n* = 2), and germ cell tumor (GCT; *n* = 1) and were of different racial and ethnic backgrounds ([Table 2](#MCS004218MACTB2){ref-type="table"}). Our analysis revealed that this particular variant is significantly enriched in the pediatric cancer population (*P* = 0.0024; OR = 3.3; 95% CI, 1.7--6.7) compared to the gnomAD noncancer cohort in which this variant accounts for 64 of 385 (17%) *RECQL4* LOF variants with a global allele frequency of 2.43 × 10^−4^. This supports the notion that the c.1573delT (p.Cys525Alafs) alteration contributes to the pathogenesis of pediatric cancer; however, its presence in a presumably healthy population suggests that it may be a lower penetrance allele.

To investigate the possible penetrance of germline *RECQL4* LOF variants, we examined the family histories of four patients from the St. Jude cohort for whom such information was available. None of these patients had first- or second-degree relatives with early onset of cancer (defined here as cancer before 50 yr of age; [Fig. 4](#MCS004218MACF4){ref-type="fig"}). This further supports the idea that heterozygous *RECQL4* LOF variants function as lower penetrance alleles. These data are consistent with the literature in which there are only rare reports of relatives of RTS patients who have developed OS ([@MCS004218MACC38]).

![Pedigrees of families with *RECQL4* LOF mutations.](MCS004218Mac_F4){#MCS004218MACF4}

Prevalence of Germline LOF Variants in Other Genes of the RecQ Helicase Family {#s2d}
------------------------------------------------------------------------------

Because the RecQ helicase genes are highly conserved, it remained possible that other family members might also be associated with childhood cancer development. Therefore, we examined the St. Jude and TARGET cohorts for heterozygous LOF variants in *RECQL*, *BLM*, *WRN*, and *RECQL5*. Through these studies, we identified 51 children with heterozygous LOF variants in one of these genes, including 13 with variants in *RECQL*, 13 with variants in *BLM*, 15 with variants in *WRN*, and 10 with variants in *RECQL5* ([Supplemental Table 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004218/-/DC1)). Pan-cancer analyses did not reveal any significant associations between the presence of heterozygous LOF variants in other RecQ helicases and pediatric cancer ([Table 3](#MCS004218MACTB3){ref-type="table"}). However, cancer-specific analyses identified a significant association in which *RECQL* variants were present in 1.2% (3 out of 249) of OS cases (*P* = 0.037; OR = 4.2; 95% CI, 1.3--13.1). Additional nonsignificant associations of potential interest include the identification of *RECQL* variants in 1.3% (2 out of 150) of rhabdomyosarcoma cases (*P* = 0.071; OR = 4.6; 95% CI, 1.2--18.7) and *WRN* variants in 0.39% (9 out of 2314) of pediatric ALL patients (*P* = 0.061; OR = 1.9; 95% CI, 0.98--3.7).

###### 

Comparison of heterozygous *RECQL4* LOF variants in pediatric cancer patients and the gnomAD noncancer cohort

  Cancer diagnosis                 Pediatric cancer patients   gnomAD noncancer cohort   Cancer risk                                
  -------------------------------- --------------------------- ------------------------- ------------- --------- ------------------ -------------
  *RECQL*                                                                                                                           
   Pan-cancer (all diagnoses)      13                          5549                      388           133,799   0.81 (0.46, 1.4)   0.52
   Osteosarcoma                    3                           246                       388           133,799   4.2 (1.3, 13.1)    0.037\*
  *BLM*                                                                                                                             
   Pan-cancer (all diagnoses)      13                          5549                      279           133,908   1.1 (0.64, 2.0)    0.65
   Osteosarcoma                    0                           249                       279           133,908   0                  1
  *WRN*                                                                                                                             
   Pan-cancer (all diagnoses)      15                          5547                      273           133,914   1.3 (0.79, 2.2)    0.29
   Osteosarcoma                    0                           249                       273           133,914   0                  1
  *RECQL4*                                                                                                                          
   Pan-cancer (all diagnoses^a^)   23                          5539                      385           133,802   1.4 (0.95, 2.2)    0.098
   Osteosarcoma                    5                           244                       385           133,802   7.1 (2.9, 17.0)    0.00087\*\*
  *RECQL5*                                                                                                                          
   Pan-cancer (all diagnoses)      10                          5552                      284           133,903   0.85 (0.45, 1.6)   0.76
   Osteosarcoma                    0                           249                       284           133,903   0                  1

\**P* \< 0.05.

\*\**P* \< 0.005.

^a^Patient with pathogenic *RB1* variant was excluded from statistical analysis.

Population Admixture of the Childhood Cancer Cohort Compared to the gnomAD Cohort {#s2e}
---------------------------------------------------------------------------------

To determine whether the enrichment of germline *RECQL4* or *RECQL* variants might be due to differences in the ethnic composition of pediatric cancer versus gnomAD noncancer cohorts, we compared the population admixtures of these two groups. Here, the ethnicity of individuals in the pediatric cancer cohort was computationally predicted ([Supplemental Fig. 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004218/-/DC1)). As shown in [Supplemental Table 3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004218/-/DC1), the population admixture in the pediatric cancer cohort is not equivalent to that found in gnomAD noncancer version 2.1. Nevertheless, all *RECQL4* and *RECQL* LOF variants are extremely rare with respect to both global and ethnicity-specific allele frequencies ([Table 2](#MCS004218MACTB2){ref-type="table"}; [Supplemental Table 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004218/-/DC1)). Therefore, it is unlikely that the differences in the composition of the two populations significantly impacts our results. To further examine this possibility, we evaluated for enrichment of germline heterozygous LOF variants in *RECQL4* using only non-Finnish Europeans who comprise the majority of individuals in the cancer and noncancer cohorts ([Supplemental Table 3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004218/-/DC1)). Through this analysis, significant enrichment in pediatric OS was once again observed for variants affecting *RECQL4* (*P* = 0.0012, OR = 6.77 \[2.79, 16.45\]) and *RECQL* (*P* = 0.024, OR = 5.04 \[1.60, 15.86\]).

DISCUSSION {#s3}
==========

As genetic testing is increasingly applied to patients with cancer, our knowledge of the germline contributions to cancer risk is dramatically expanding. Through such efforts, it has become clear that heterozygous pathogenic variants in DNA damage repair genes, such as *ATM*, *BRCA2*, and *PALB2*, are associated with a significant increase in risk to develop certain cancers. Here, we examined whether heterozygous LOF variants in *RECQL4*, the gene encoding an important DNA helicase that is mutated in individuals with RTS, are more prevalent in children with cancer.

After screening 5562 pediatric cases, we identified a significant enrichment of heterozygous germline *RECQL4* LOF variants in patients with OS, the most common cancer in RTS, which is caused by homozygous or compound heterozygous variants in *RECQL4*. Although not significantly overrepresented, such variants were also identified in children with other tumor types, such as ALL, AML, craniopharyngioma, GCT, HL, and NHL. In 12 cases for whom tumor data were available, no deletions or mutations within the remaining *RECQL4* allele were detected. Although other mechanisms might account for a second hit (e.g., changes in methylation) ([@MCS004218MACC25]; [@MCS004218MACC11]), it remains possible that RECQL4 haploinsufficiency, perhaps in combination with other oncogenic events, is enough to promote malignant transformation.

Our findings are consistent with recent studies documenting heterozygous germline *RECQL4* variants in adults with a variety of malignancies ([@MCS004218MACC36]; [@MCS004218MACC17]; [@MCS004218MACC24]; [@MCS004218MACC42]; [@MCS004218MACC2]; [@MCS004218MACC4]; [@MCS004218MACC22]; [@MCS004218MACC26]; [@MCS004218MACC28]; [@MCS004218MACC29]; [@MCS004218MACC30]; [@MCS004218MACC39]). In addition to these studies are reports of an increased prevalence of *RECQL4* variants in patients with bladder ([@MCS004218MACC26]) or colorectal cancer ([@MCS004218MACC2]) compared to the general population. Moreover, a heterozygous germline truncating variant in *RECQL4* has been implicated as a possible cancer risk factor in an individual with prostate cancer ([@MCS004218MACC28]). Curiously, a previous investigation did not find enrichment of *RECQL4* mutations in sporadic cases of OS compared to the general population ([@MCS004218MACC27]); however, this prior study examined a much smaller cohort including only 71 patients with OS. Thus, this association could potentially have been missed.

Among the 24 patients identified as harboring a single germline *RECQL4* LOF variant, 17 (71%) of these variants reside in the highly conserved helicase domain, with nine of these carrying the same c.1573delT (p.Cys525Alafs) alteration. Most RTS patients also harbor variants that result in a truncated protein lacking some or all of the helicase domain. Correspondingly, it has been reported that many RTS patients who developed OS harbor at least one truncating variant in *RECQL4*, whereas individuals with a clinical diagnosis of RTS and either a missense variant or no identified variant in *RECQL4* were not reported to develop OS ([@MCS004218MACC48]). In contrast to these deleterious truncating variants, the hallmark variant in RAPADILINO syndrome, a splice site variant that causes in-frame skipping of exon 7 ([@MCS004218MACC45]), leaves the helicase domain largely intact ([@MCS004218MACC18]; [@MCS004218MACC37]), which may correspond with the lower incidence of cancer.

In addition to the new association of heterozygous germline *RECQL4* LOF variants with pediatric OS, our data also showed evidence of an association linking *RECQL* variants with OS, which deserves further investigation. Germline *RECQL* variants have been reported in *BRCA1/2-*negative breast cancers ([@MCS004218MACC10]; [@MCS004218MACC40]; [@MCS004218MACC19]); however, this association is disputed ([@MCS004218MACC19]; [@MCS004218MACC21]). To date, *RECQL* variants have not been reported in pediatric cancer. No strong associations were found between pediatric cancer and germline heterozygous LOF variants in the other RecQ helicase genes (i.e., *BLM*, *WRN*, *RECQL5*). Although all RecQ helicase genes contain the highly conserved helicase domain ([@MCS004218MACC15]), they each play unique roles in genome maintenance and stability ([@MCS004218MACC9]). Toward this end, previous work has demonstrated that only two of the five human RecQ helicases, *RECQL* and *RECQL4*, bind specifically to three well-defined DNA replication origins under native conditions ([@MCS004218MACC43]), whereas the other helicases (i.e., *BLM*, *WRN*, *RECQL5)* can only be found at replication origins following treatment with replication inhibitors ([@MCS004218MACC43]). The similar localization and putative roles of *RECQL* and *RECQL4* may underlie how disruption of these helicases promotes the development of OS and possibly other cancers.

This study has several limitations. First, the prevalence of germline *RECQL4* variants identified in this study might not reflect the prevalence in newly diagnosed pediatric cancer patients because 50% of the patients studied were long-term survivors of childhood cancer. If the presence of heterozygous germline LOF variants is associated with poorer (or better) outcomes, it is possible that their prevalence in our cohort will be lower (or higher) than in newly diagnosed patients. A second limitation is that the population admixture of the pediatric cancer cohort examined in this study is not equivalent to that found in the gnomAD noncancer cohort ([Supplemental Data](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004218/-/DC1)). We suspect that this is due to differences in outcomes or referral patterns among different populations. Regardless, all of the LOF alleles reported in this study are extremely rare with respect to both global and ethnicity-specific allele frequencies. Last, this study is limited by the small number of individuals who harbor germline LOF variants. This factor makes it difficult to define the true spectrum of cancers associated with these germline variants. Continued evaluation of patients with cancer for the presence of heterozygous germline *RECQL4* LOF variants, and LOF variants in the other RecQ helicase genes, is warranted to validate and refine this new association.

METHODS {#s4}
=======

Study Participants {#s4a}
------------------

Study participants were from the Pediatric Cancer Genome Project (*n* = 1120), Genomes for Kids protocol (*n* = 309), St. Jude Lifetime Cohort (SJLIFE) Study (*n* = 3006), and Therapeutically Applicable Research to Generate Effective Treatment (TARGET) program (*n* = 1127). The index case consented to participate in an IRB-approved study at St. Jude Children\'s Research Hospital that specifically allowed for germline interrogation and reporting.

Variant Detection and Classification {#s4b}
------------------------------------

Single-nucleotide variants, small insertions and deletions, and copy-number variations were detected from whole-exome and/or genome sequencing (WGS) of the germline as previously described ([@MCS004218MACC50]; [@MCS004218MACC35]). Genetic variants were annotated, and LOF variants were further analyzed.

Curation of LOF Variants in gnomAD {#s4c}
----------------------------------

Variants in RecQ helicase genes (*RECQL*, *BLM*, *WRN*, *RECQL4*, *RECQL5*) in the noncancer subset of the Genome Aggregation Database (gnomAD v2.1) were queried ([Supplemental Tables 4--8](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004218/-/DC1)). The putative LOF variants in gnomAD noncancer set v2.1 were downloaded first, and subsequently all variants of dubious quality via the tags "Flag" = "lc_lof" (low confidence-loss-of-function) were excluded. Variants with the "Flag" = "lcr" or "Flag" = "segdup" were reviewed and retained if they passed the quality control and manual curation steps. In the case of *RECQL4*, the founder variant, c.1390+2delT (p.Ala420_Ala463del), was removed as it is commonly encountered in the Finnish population at a minor allele frequency of 0.4% ([@MCS004218MACC20]) but was absent from our cohort.

Statistical Analysis {#s4d}
--------------------

Statistical analysis of population enrichment was calculated via a 2 × 2 Fisher\'s exact test, and estimates of the OR were performed using the RStudio R statistical computing environment with the epiR package (<https://CRAN.R-project.org/package=epiR>). Statistical significance was defined by a two-sided *P* = 0.05.

Computational Prediction of Ethnicity {#s4e}
-------------------------------------

Data from our pediatric cancer cohort (comprised of 4435 pediatric cancer patients at St. Jude Children\'s Research Hospital and 1127 from the National Cancer Institute TARGET database) was combined with data from 1000 Genomes, and the principal components (PCs) were extracted. Ethnicity data from 1000 Genomes were then used to train a random forest using the top 10 PCs which was used to predict the ethnicity of individuals in the pediatric cancer cohort. A visualization of the unsupervised ethnicity clustering is shown in [Supplemental Figure 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004218/-/DC1).

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

Genomic sequence data from St. Jude Children\'s Research Hospital is available for request on the St. Jude Cloud Platform. The variants were submitted to ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) and can be found under accession numbers SCV000288218.6 and SCV000890968.1.
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